Skip to main content

Reset your password

Please enter the e-mail address you used to register to reset your password

Note: The verification e-mail to change your password should arrive immediately. However, in some cases it takes longer. Don't forget to check your spam folder.

If you haven't received the e-mail in 24 hours, please contact customerservices@ioppublishing.org

Registration complete

Thank you for registering with Physics World
If you'd like to change your details at any time, please visit My account

Close
Home » Page 143

Quantum showcase sets out next decade of UK quantum

Described as “the Glastonbury of quantum events” by one speaker, the UK National Quantum Technologies Showcase 2024 last week was the first time I have ever queued for a physics event. Essentially a quantum trade show, the showcase has been running for a decade, and in that time its attendance has grown from 100 to nearly 2000. It’s run by Innovate UK in collaboration with the Engineering and Physical Sciences Research Council (EPSRC) and the UK National Quantum Technologies Programme (NQTP).

Nearly 100 quantum companies exhibited and there were talks and panels throughout the day. The mood was triumphant – last year the UK government announced the next phase of the NQTP, backed by a £2.5 billion 10-year quantum strategy, and in September, five quantum hubs were launched at British universities (with some overlap with the four previous hubs). However, for a sector that’s still finding its feet, the increasing focus on commercialization and industry creates some interesting tensions.

Commitment to quantum

Most of the funding for quantum technologies research in the UK comes from the public sector, and in the wake of the election of a new government, the organizers clearly felt a need to assuage post-election jitters.

The first speaker was Dave Smith, the UK’s national technology adviser, who gave an ambitious outline of the next decade of the government’s quantum strategy, which he expects to “grow the economy and make people’s lives better”. To do this, the UK quantum sector needs two things: talent and money. Smith’s speech focussed on the need to attract overseas talent, train apprentices and PhD students, and encourage private investors to dip their toes into quantum.

“We’ve gone from the preserve of academia to real-world applications” said Stella Peace, the recently appointed interim executive chair of Innovate UK, who spoke next. Her address made similar points to Smith, emphasizing that as well as funding quantum directly, Innovate UK aims to create connections between academia and industry that will grow the sector.

One senior figure with experience of the industry, government and academia aspects of quantum technology is the physicist Peter Knight from Imperial College London, who has been involved in the NQTP since it started and is now the chair of its strategic advisory board. Knight gave an insightful first-hand account of the last decade of the UK’s quantum programme. He said he was reassured that the new government is committed to quantum technology, but as with anything involving billions of pounds, making this a priority hasn’t been easy and Knight’s work is far from over. He described the researchers who led the first quantum hubs as “heroes” but added that “you can be heroic and fail”. According to Knight, to realize the potential of quantum technologies, “we need more than heroes, we need money”.

I spent the rest of the day alternating between the exhibition area and the talks. I saw established companies like Toshiba and British Telecom (BT) that are branching into quantum, as well as start-ups including Phasecraft and Quantum Dice.

A lively panel event on quantum skills was a particular highlight. The quantum sector faces a shortage of engineers, and the panellists debated whether quantum science should be integrated into existing engineering degrees and apprenticeships. A dissenting voice came from Rhys Morgan, the director of engineering and education at the Royal Academy of Engineering. “I’m not sure I agree with the need for a quantum apprenticeship,” he said, arguing that quantum companies should be training engineers on the job rather than expecting them to specialize during their degree.

Quantum at the crossroads

The UK government plans to invest £2.5bn in quantum technologies over the next decade and wants to attract an additional £1bn from private investment. The goal is to achieve a “quantum-enabled economy” by 2033. “Over the next 10 years,” states the National Quantum Strategy, “quantum technologies will revolutionize many aspects of life in the UK and bring enormous benefits to the UK economy, society and the way we can protect our planet.”

This is a bold statement. It sounds like the government expects to start getting a return on its quantum investment in the near future. But is that realistic?

“Quantum technologies” is an imprecise term, but where it refers to computing and communications, it’s still firmly in the research phase of research and development. Even quantum sensing start-ups like Cerca Magnetics and Delta G are just starting to move towards commercialization. Quantum research has made huge strides but scientists and companies should be realistic about its current capabilities and advocate for space and time to explore work that might not come to fruition in the next decade.

This was summed up in the final address from Roger Mckinley, the quantum technologies challenge director at UK Research and Innovation (UKRI). His message to the government was that quantum commercialization is going to happen, but that they need to ask themselves: “How much do you want this to happen in the UK?”

Whatever you think about the hype over quantum technologies, researchers in the UK can celebrate the last decade, in which the country has punched above its weight in terms of quantum investment and research. However, there’s a lot of work still to do. If quantum researchers are serious about bringing these technologies to the real world, they should be prepared to keep fighting for them.

How Albert Einstein and John Bell inspired Artur Ekert’s breakthrough in quantum cryptography

If you love science and are near London, the Royal Society runs a wonderful series of public events that are free of charge. This week, I had the pleasure of attending the Royal Society Milner Prize Lecture, which was given by the quantum cryptography pioneer Artur Ekert. The prize is described as “the premier European award for outstanding achievement in computer science” and his lecture was called “Privacy for the paranoid ones: the ultimate limits of secrecy“. I travelled up from Bristol to see the lecture and I enjoyed it very much.

Ekert has academic appointments at the University of Oxford, the National University of Singapore and the Okinawa Institute of Technology. He bagged this year’s prize, “For his pioneering contributions to quantum communication and computation, which transformed the field of quantum information science from a niche academic activity into a vibrant interdisciplinary field of industrial relevance”.

Ekert is perhaps most famous for his invention in 1991 of entanglement-based quantum cryptography. However, his lecture kicked-off several millennia earlier with an example of a permutation cypher called a scytale. Used by the ancient Greeks, the cypher conceals a message in a series of letters written on a strip of paper. When the paper is wound around a cylinder of the correct radius, the message appears – so not that difficult to decipher if you have a set of cylinders of different radii.

Several hundred years later things had improved somewhat, with the Romans using substitution cyphers whereby letters are substituted for each other according to a secret key that is shared by sender and receiver. The problem with this, explained Ekert, is that if the same key is used to encrypt multiple messages, patterns will emerge in the secret messages. For example, “e” is the most common letter in English, and if it is substituted by “p”, then that letter will be the most common letter in the encrypted messages.

Maths and codebreaking

Ekert said that this statistical codebreaking technique was developed in the 9th century by the Arab polymath Al-Kindi. This appears to be the start of the centuries-long relationship between mathematicians and code makers and breakers that thrives today at places like the UK’s Government Communications Headquarters (GCHQ).

Substitution cyphers can be improved by constantly changing the key, but then the problem becomes how to distribute keys in a secure way – and that’s where quantum physics comes in. While classical key distribution protocols like RSA are very difficult to crack, quantum protocols can be proven to be unbreakable – assuming that they are implemented properly.

Ekert’s entanglement-based protocol is called E91, and he explained how it has its roots in the Einstein–Podolsky–Rosen (EPR) paradox. This is a thought experiment that was devised in 1935 by Albert Einstein and colleagues to show that quantum mechanics was “incomplete” in how it described reality. They argued that classical physics with extra “hidden variables” could explain correlations that arise when measurements are made on two particles that are in what we now call a quantum-entangled state.

Ekert then fast-forwarded nearly three decades to 1964, when the Northern Irish physicist John Bell came up with a mathematical framework to test whether an entangled quantum state can indeed be described using classical physics and hidden variables. Starting in the 1970s, physicists did a series of experiments called Bell tests that have established that correlations observed in quantum systems cannot be explained by classical physics and hidden variables. This work led to John Clauser, Alain Aspect and Anton Zeilinger sharing the 2022 Nobel Prize for Physics.

Test for eavesdropping

In 1991, Ekert realised that a Bell test could be used to reveal whether a secret communication using entangled photons had been intercepted by an eavesdropper. The idea is that the eavesdropper’s act of measurement would destroy entanglement and leave the photon pairs with classical, rather than quantum, correlations.

That year, Ekert along with John Rarity and Paul Tapster demonstrated E91 at the UK’s Defence Research Agency in Malvern. In the intervening decades E91 and other quantum key distribution (QKD) protocols have been implemented in a number of different scenarios – including satellite communications – and some QKD protocols are commercially available.

However, Ekert points out that quantum solutions are not available for all cryptographic applications – they tend to work best for the exchange of messages, rather than the password protection of documents, for example. He also said that developers and users must ensure that QKD protocols are implemented properly using equipment that works as expected. Indeed, Ekert points out that the current interest in identifying and closing “Bell loopholes” is related to QKD. Loopholes are situations where classical phenomena could inadvertently affect a Bell test, making a classical system appear quantum.

So, there is much more work for Ekert and his colleagues to do in quantum cryptography. And if the enthusiasm of his talk is any indication, Ekert is up for the challenge.

Physicists in cancer radiotherapy

The programme focuses on the cancer radiation therapy patient pathway, with the aim of equipping students with the skills to progress onto careers in clinical, academic research or commercial medical physics opportunities.

Alan McWilliam, programme director of the new course, is also a reader in translational radiotherapy physics. He explains: “Radiotherapy is a mainstay of cancer treatment, used in around 50% of all treatments, and can be used together with surgery or systemic treatments like chemotherapy or immunotherapy. With a heritage dating back over 100 years, radiotherapy is now highly technical, allowing the radiation to be delivered with pin-point accuracy and is increasingly interdisciplinary to ensure a high-quality, curative delivery of radiation to every patient.”

“This new course builds on the research expertise at Manchester and benefits from being part of one of the largest university cancer departments in Europe, covering all aspects of cancer research. We believe this master’s reflects the modern field of medical physics, spanning the multidisciplinary nature of the field.”

Cancer pioneers

Manchester has a long history of developing solutions to drive improvements in healthcare, patients’ lives and the wellbeing of individuals. This new course draws on scientific research and innovation to equip those interested in a career in medical physics or cancer research with specialist skills that draw on a breadth of knowledge.  Indeed, the course units bring together expertise from academics that have pioneered, amongst other work, the use of image-guided radiotherapy, big data analysis using real-world radiotherapy data, novel MR imaging for tracking oxygenation of tumours during radiotherapy, and proton research beam lines. Students will benefit directly from this network of research groups by being able to join research seminars throughout the course.

Working with clinical scientists

The master’s course is taught together with clinical physicists from The Christie NHS Foundation Trust, one of the largest single-site cancer hospitals in Europe and the only UK cancer hospital connected directly to a research institute. The radiotherapy department currently has 16 linear accelerators across four sites, an MR-guided radiotherapy service and one of the two NHS high-energy proton beam services. The Christie is currently one of only two cancer centres in the world with access to both proton beam and an MR-guided linear accelerator. For students, this partnership provides the opportunity to work with people at the forefront of cancer treatment developments.

To reflect the current state of radiotherapy, the University of Manchester has worked with The Christie to ensure students gain the skills necessary for a successful, modern, medical physics career. Units have a strong clinical focus, with access to technology that allows students to experience and learn from clinical workflows.

Students will learn the fundamentals of how radiotherapy works, from interactions of X-rays and matter, through X-ray beam generation control and measurement, and to how treatments are planned. Complementary to X-ray therapy, students will learn about the concepts of proton beam therapy, how the delivery of protons is different from X-rays, and the potential clinical benefits and unique difficulties of protons due to greater uncertainties from how protons interact with matter.

Delivering radiation with pin-point accuracy

The course will provide an in-depth understanding of how imaging can be used throughout the patient pathway to aid treatment decisions and guide the delivery of radiation.

The utility of CT, MRI and PET scanners across clinical pathways is explored, and the area of radiation delivery is complemented by material on radiobiology – how cells and tissues respond to radiation.

The difference between the response of tumours and normal tissue to radiation is called the therapeutic ratio. The radiobiology teaching will focus on how to maximize this ratio, essentially how to improve cure whilst minimising the risk of side-effects due to irradiation of nearby normal tissues. Students will also explore how this ratio could be enhanced or modified to improve the efficacy of all forms of radiotherapy.

Research and technology

A core strength of the research groups in Manchester is the use of routinely collected data in the evaluation of improvements in treatment delivery or the clinical translation of research findings. Many such improvements do not qualify for a full randomized clinical trial. However, there are many pragmatic methods to evaluate clinical benefit. Through studying clinical workflows and translation, these concepts will be explored along with investigating how to maximise results from all available data.

Modern medical physicists need an appreciation of artificial intelligence (AI). AI is emerging as an automation tool throughout the radiation therapy workflow; for example, segmentation of tissues, radiotherapy planning and quality assurance. This course delves into the fundamentals of AI and machine learning, giving students the opportunity to implement their own solution for image classification or image segmentation. For those with leadership aspirations, guest lecturers from various academic, clinical or commercial backgrounds will detail career routes and how to develop knowledge in this area.

Pioneering new learning and assessments

Programme director Alan McWilliam talks us through the design of the course and how students are evaluated:

“An aspect of the teaching we are particularly proud of is the design of the assessments throughout the units. Gone are written exams, with assessments allowing students to apply their new knowledge to real medical physics problems. Students will perform dosimetric calculations and Monte Carlo simulations of proton depositions, as well as build an image registration pipeline and pitch for funding in a dragon’s den (or shark tank) scenario. This form of assessment will allow students to demonstrate skills directly useful for future career pathways.”

“The final part of the course is the research project, to take place after the taught elements are complete. Students will choose from projects which will embed them with one of the academic or clinical groups. Examples for the current cohort include training an AI segmentation model for muscle in CT images and associating this with treatment outcomes; simulating prompt gamma rays from proton deliveries for dose verification; and assisting with commissioning MR-guided workflows for ultra-central lung treatments.”

Develop your specialist skills

The Medical Physics in Cancer Radiation Therapy MSc is a one-year full-time (two-year part-time) programme at the University of Manchester.

Applications are now open for the next academic year, and it is recommended to apply early, as applications may close if the course is full.

Find out more and apply: https://uom.link/medphyscancer 

EU must double its science budget to remain competitive, warns report

The European Union should more than double its budget for research and innovation in its next spending round, dubbed Framework Programme 10 (FP10). That’s the view of a report by an expert group, which says a dramatic increase to €220bn is needed for European science to be globally competitive once again. Its recommendations are expected to have a big influence over the European Commission’s proposals for FP10, due in mid-2025.

The EU’s current Horizon Europe programme, which runs from 2021 to 2027, has a budget of €95.5bn. In December 2023, the Commission picked 15 experts from research and industry – led by former Portuguese science minister Manuel Heitor – to advise on FP10, which is set to run from 2028 to 2034. According to their report, Europe is lagging behind in investment and impact in science, technology and innovation.

It says Europe’s share of global scientific publications, most-cited publications and patent applications have dropped over the last 20 years. Europe’s technology base, it claims, is more diverse than other major economies, but also more focused on less complex technologies. China and the US, in contrast, lead in areas expected to drive future growth, such as semiconductors, optics, digital communications and audio-visual technologies.

The experts also say the “disruptive, paradigm shifting research and innovation” that Europe needs to boast it economies is “unlikely to be fostered by conventional procedures and programmes in the EU today”. They want the EU to set up an experimental unit to test and launch disruptive innovation programmes with “fast funding” options. It should develop programmes like those of the US advanced research projects agencies and explore how generative AI could be used in science.

Based on analysis of previous unfunded proposals, the report claims that FP10’s budget should be doubled to €220bn to “guarantee funding of all high-quality proposals”. It also says that funding applications need to be simplified and streamlined, with funding handed out more quickly. It also calls for better international collaborations, including with China, and disruptive innovation programmes, such as on military-civilian “dual-use” innovation.

Launching the report, Heitor said there was a need “to put research technology and innovation in the centre of European economies”, adding that the expert group was calling for “radical simplification and innovation” for the next programme. Europe needs to pursue a “transformative agenda” in FP10 around four interlinked areas: competitive excellence in science and innovation; industrial competitiveness; societal challenges; and a strong European research and innovation ecosystem.

Space travel: the health effects of space radiation and building a lunar GPS

We are entering a second golden age of space travel – with human missions to the Moon and Mars planned for the near future. In this episode of the Physics World Weekly podcast we explore two very different challenges facing the next generation of cosmic explorers.

First up, the radiation oncologist James Welsh chats with Physics World’s Tami Freeman about his new ebook about the biological effects of space radiation on astronauts. They talk about the types and origins of space radiation and how they impact human health. Despite the real dangers, Welsh explains that the human body appears to be more resilient to radiation than are the microelectronics used on spacecraft. Based at Loyola Medicine in the US, Welsh explains why damage to computers, rather than the health of astronauts, could be the limiting factor for space exploration.

Later in the episode I am in conversation with two physicists who have written a paper about how we could implement a universal time standard for the Moon. Based at the US’s National Institute of Standards and Technology (NIST), Biju Patla and Neil Ashby, explain how atomic clocks could be used to create a time system that would making coordinating lunar activities easier – and could operate as a GPS-like system to facilitate navigation. They also say that such a lunar system could be a prototype for a more ambitious system on Mars.

Further reading

Welsh’s ebook is called “Space Radiation: Astrophysical origins, radiobiological effects and implications for space travellers”. It is part of the IPEM–IOP Series in Physics and Engineering in Medicine and Biology.

Ashby and Patla’s paper is called “A Relativistic Framework to Estimate Clock Rates on the Moon” and it appears in The Astronomical Journal.

Hybrid irradiation could facilitate clinical translation of FLASH radiotherapy

Dosimetric comparisons of prostate cancer treatment plans
Dosimetric comparisons Treatment plans for a prostate cancer patient, showing the dose distributions for a conventional dose rate (CDR) plan, a hybrid ultrahigh-dose rate (UHDR)–conventional (HUC) plan, and the UHDR part of the HUC plan, delivered by a 250 MeV electron field. (Courtesy: CC BY 4.0/Radiother. Oncol. 10.1016/j.radonc.2024.110576)

FLASH radiotherapy is an emerging cancer treatment that delivers radiation at extremely high dose rates within a fraction of a second. This innovative radiation delivery technique, dramatically faster than conventional radiotherapy, reduces radiation injury to surrounding healthy tissues while effectively targeting malignant tumour cells.

Preclinical studies of laboratory animals have demonstrated that FLASH radiotherapy is at least equivalent to conventional radiotherapy, and may produce better anti-tumour effects in some types of cancer. The biological “FLASH effect”, which is observed for ultrahigh-dose rate (UHDR) irradiations, spares normal tissue compared with conventional dose rate (CDR) irradiations, while retaining the tumour toxicity.

With FLASH radiotherapy opening up the therapeutic window, it has potential to benefit patients requiring radiotherapy. As such, efforts are underway worldwide to overcome the clinical challenges for safe adoption of FLASH into clinical practice. As the FLASH effect has been mostly investigated using broad UHDR electron beams, which have limited range and are best suited for treating superficial lesions, one important challenge is to find a way to effectively treat deep-seated tumours.

In a proof-of-concept treatment planning study, researchers in Switzerland demonstrated that a hybrid approach combining UHDR electron and CDR photon radiotherapy may achieve equivalent dosimetric effectiveness and quality to conventional radiotherapy, for the treatment of glioblastoma, pancreatic cancer and localized prostate cancer. The team, at Lausanne University Hospital and the University of Lausanne, report the findings in Radiotherapy and Oncology.

Combined device

This hybrid treatment could be facilitated using a linear accelerator (linac) with the capability to generate both UHDR electron beams and CDR photon beams. Such a radiotherapy device could eliminate concerns relating to the purchase, operational and maintenance costs of other proposed FLASH treatment devices. It would also overcome the logistical hurdles of needing to move patients between two separate radiotherapy treatment rooms and immobilize them identically twice.

For their study, the Lausanne team presumed that such a dual-use clinically approved linac exists. This linac would deliver a bulk radiation dose by a UHDR electron beam in a less conformal manner to achieve the FLASH effect, and then deliver conventional intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT) to enhance dosimetric target coverage and conformity.

Principal investigator Till Böhlen and colleagues created a machine model that simulates 3D-conformal broad electron beams with a homogeneous parallel fluence. They developed treatments that deliver a single broad UHDR electron beam with case-dependent energy of between 20 and 250 MeV for every treatment fraction, together with a CDR VMAT to produce a conformal dose delivery to the planning target volume (PTV).

The tumours for each of the three cancer cases required simple, mostly round PTVs that could be covered by a single electron beam. Each plan’s goal was to deliver the majority of the dose per treatment with the UHDR electron beam, while achieving acceptable PTV coverage, homogeneity and sparing of critical organs-at-risk.

Plan comparisons

The researchers assessed the plan quality based on absorbed dose distribution, dose–volume histograms and dose metric comparisons with the CDR reference plans used for clinical treatments. In all cases, the hybrid plans exhibited comparable dosimetric quality to the clinical plans. They also evaluated dose metrics for the parts of the doses delivered by the UHDR electron beam and by the CDR VMAT, observing that the hybrid plans delivered the majority of the PTV dose, and large parts of doses to surrounding tissues, at UHDR.

“This study demonstrates that hybrid treatments combining an UHDR electron field with a CDR VMAT may provide dosimetrically conformal treatments for tumours with simple target shapes in various body sites and depths in the patient, while delivering the majority of the prescribed dose per fraction at UHDR without delivery pauses,” the researchers write.

In another part of the study, the researchers estimated the potential FLASH sparing effect achievable with their hybrid technique, using the glioblastoma case as an example. They assumed a FLASH normal tissue sparing scenario with an onset of FLASH sparing at a threshold dose of 11 Gy/fraction, and a more favourable scenario with sparing onset at 3 Gy/fraction. The treatment comprised a single-fraction 15 Gy UHDR electron boost, supplemented with 26 fractions of CDR VMAT. The two tested scenarios showed a FLASH sparing magnitude of 10% for the first scenario and more substantial 32% sparing of brain tissues of for the second.

“Following up on this pilot study focusing on feasibility, the team is currently working on improving the joint optimization of the UHDR and CDR dose components to further enhance plan quality, flexibility and UHDR proportion of the delivered dose using the [hybrid] treatment approach,” Böhlen tells Physics World. “Additional work focuses on quantifying its biological benefits and advancing its technical realization.”

Trailblazer: astronaut Eileen Collins reflects on space, adventure, and the power of lifelong learning

In this episode of Physics World Stories, astronaut Eileen Collins shares her extraordinary journey as the first woman to pilot and command a spacecraft. Collins broke barriers in space exploration, inspiring generations with her courage and commitment to discovery. Reflecting on her career, she discusses not only her time in space but also her lifelong sense of adventure and her recent passion for reading history books. Today, Collins frequently shares her experiences with audiences around the world, encouraging curiosity and inspiring others to pursue their dreams.

Joining the conversation is Hannah Berryman, director of the new documentary SPACEWOMAN, which is based on Collins’ memoir Through the Glass Ceiling to the Stars, co-written with Jonathan H Ward. The British filmmaker describes what attracted her to Collins’ story and the universal messages it reveals. Hosted by science communicator Andrew Glester, this episode offers a glimpse into the life of a true explorer – one whose spirit of adventure knows no bounds.

SPACEWOMAN has its world premiere on 16 November 2024 at DOC NYC. Keep an eye on the documentary’s website for details of how you can watch the film wherever you are.

Venkat Srinivasan: ‘Batteries are largely bipartisan’

Which battery technologies are you focusing on at Argonne?

We work on everything. We work on lead-acid batteries, a technology that’s 100 years old, because the research community is saying, “If only we could solve this problem with cycle life in lead-acid batteries, we could use them for energy storage to add resilience to the electrical grid.” That’s an attractive prospect because lead-acid batteries are extremely cheap, and you can recycle them easily.

We work a lot on lithium-ion batteries, which is what you find in your electric car and your cell phone. The big challenge there is that lithium-ion batteries use nickel and cobalt, and while you can get nickel from a few places, most of the cobalt comes from the Democratic Republic of Congo, where there are safety and environmental concerns about exactly how that cobalt is being mined, and who is doing the mining. Then there’s lithium itself. The supply chain for lithium is concentrated in China, and we saw during COVID the problems that can cause. You have one disruption somewhere and the whole supply chain collapses.

We’re also looking at technologies beyond lithium-ion batteries. If you want to start using batteries for aviation, you need batteries with a long range, and for that you have to increase energy density. So we work on things like solid-state batteries.

Finally, we are working on what I would consider really “out there” technologies, where it might be 20 years before we see them used. Examples might be lithium-oxygen or lithium-sulphur batteries, but there’s also a move to go beyond lithium because of the supply chain issues I mentioned. One alternative might be to switch to sodium-based batteries. There’s a big supply of soda ash in the US, which is the raw material for sodium, and sodium batteries would allow us to eliminate cobalt while using very little nickel. If we can do that, the US can be completely reliant on its own domestic minerals and materials for batteries.

What are the challenges associated with these different technologies?

Frankly, every chemistry has its challenges, but I can give you an example.

If you look at the periodic table, the most electronegative element is lithium, while the most electropositive is fluorine. So you might think the ultimate battery would be lithium-fluorine. But in practice, nobody should be using fluorine – it’s super dangerous. The next best option is lithium-oxygen, which is nice because you can get oxygen from the air, although you have to purify it first. The energy density of a lithium-oxygen battery is comparable to that of gasoline, and that is why people have been trying to make solid-state lithium-metal batteries since before I was born.

Photo of Arturo Gutierrez and Venkat Srinivasan. Gutierrez is wearing safety glasses and a white lab coat and has his arms inside a glovebox while Srinivasan looks on
Building batteries: Venkat Srinivasan (right) discusses battery research with materials scientist Arturo Gutierrez in one of the energy storage discovery labs at Argonne National Laboratory. (Courtesy: Argonne National Laboratory)

The problem is that when you charge a battery with a lithium metal anode, the electrolyte deposits on the lithium metal, and unfortunately it doesn’t create a thin, planar layer. Instead, it forms these needle-like structures called dendrites that short to the battery’s separator. Battery shorting is never a good thing.

Now, if you put a mechanically hard material next to the lithium metal, you can stop the dendrites from growing through. It’s like putting in a concrete wall next to the roots of a tree to stop the roots growing into the other side. But if you have a crack in your concrete wall, the roots will find a way – they will actually crack the concrete – and exactly the same thing happens with dendrites.

So the question becomes, “Can we make a defect-free electrolyte that will stop the dendrites?” Companies have taken a shot at this, and on the small scale, things look great: if you’re making one or two devices, you can have incredible control. But in a large-format manufacturing setup where you’re trying to make hundreds of devices per second, even a single defect can come back to bite you. Going from the lab scale to the manufacturing scale is such a challenge.

What are the major goals in battery research right now?

It depends on the application. For electric cars, we still have to get the cost down, and my sense is that we’ll ultimately need batteries that charge in five minutes because that’s how long it takes to refuel a gasoline-powered car. I worry about safety, too, and of course there’s the supply-chain issue I mentioned.

But if you forget about supply chains for a second, I think if we can get fast charging with incredibly safe batteries while reducing the cost by a factor of two, we are golden. We’ll be able to do all sorts of things.

A researcher holding a plug kneels next to an electric car. The car has a sign on the front door that reads "Argonne research vehicle"
Charging up: Developing better batteries for electric vehicles is a major goal of research in Argonne’s ACCESS collaboration. (Courtesy: Argonne National Laboratory)

For aviation, it’s a different story. We think the targets are anywhere from increasing energy density by a factor of two for the air taxi market, all the way to a factor of six if you want an electric 737 that can fly from Chicago to Washington, DC with 75 passengers. That’s kind of hard. It may be impossible. You can go for a hybrid design, in which case you will not need as much energy density, but you need a lot of power density because even when you’re landing, you still have to defy gravity. That means you need power even when the vehicle is in its lowest state of charge.

The political landscape in the US is shifting as the Biden administration, which has been very focused on clean energy, makes way for a second presidential term for Donald Trump, who is not interested in reducing carbon emissions. How do you see that impacting battery research?

If you look at this question historically, ReCell, which is Argonne’s R&D centre for battery recycling, got established during the first Trump administration. Around the same time, we got the Federal Consortium for Advanced Batteries, which brought together the Department of Energy, the Department of Defense, the intelligence community, the State Department and the Department of Commerce. The reason all those groups were interested in batteries is that there’s a growing feeling that we need to have energy independence in the US when it comes to supply chains for batteries. It’s an important technology, there’s lots of innovations, and we need to find a way to move them to market.

So that came about during the Trump administration, and then the Biden administration doubled down on it. What that tells me is that batteries are largely bipartisan, and I think that’s at least partly because you can have different motivations for buying them. Many of my neighbours aren’t particularly thinking about carbon emissions when they buy an electric vehicle (EV). They just want to go from zero to 60 in three seconds. They love the experience. Similarly, people love to be off-grid, because they feel like they’re controlling their own stuff. I suspect that because of this, there will continue to be largely bipartisan support for EVs. I remain hopeful that that’s what will happen.

  • Venkat Srinivasan will appear alongside William Mustain and Martin Freer at a Physics World Live panel discussion on battery technologies on 21 November 2024. Sign up here.

UK plans £22bn splurge on carbon capture and storage

Further details have emerged over the UK government’s pledge to spend almost £22bn on carbon capture and storage (CCS) in the next 25 years. While some climate scientists feel the money is vital to decarbonise heavy industry, others have raised concerns about the technology itself, including its feasibility at scale and potential to extend fossil fuel use rather than expanding renewable energy and other low-carbon technologies.

In 2023 the UK emitted about 380 million tonnes of carbon dioxide equivalent and the government claims that CCS could remove more than 8.5 million tonnes each year as part of its effort to be net-zero by 2050. Although there are currently no commercial CCS facilities in the UK, last year the previous Conservative government announced funding for two industrial clusters: HyNet in Merseyside and the East Coast Cluster in Teesside.

Projects at both clusters will capture carbon dioxide from various industrial sites, including hydrogen plants, a waste incinerator, a gas-fired power station and a cement works. The gas will then be transported down pipes to offshore storage sites, such as depleted oil and gas fields. According to the new Labour government, the plans will create 4000 jobs, with the wider CCS industry potentially supporting 50,000 roles.

Government ministers claim the strategy will make the UK a global leader in CCS and hydrogen production and is expected to attract £8bn in private investment. Rachel Reeves, the chancellor, said in September that CCS is a “game-changing technology” that will “ignite growth”. The Conservative’s strategy also included plans to set up two other clusters but no progress has been made on these yet.

The new investment in CCS comes after advice from the independent Climate Change Committee, which said it is necessary for decarbonising the UK’s heavy industry and for the UK to reach its net-zero target. The International Energy Agency (IEA) and the Intergovernmental Panel on Climate Change have also endorsed CCS as critical for decarbonisation, particularly in heavy industry.

“The world is going to generate more carbon dioxide from burning fossil fuels than we can afford to dump into the atmosphere,” says Myles Allen, a climatologist at the University of Oxford. “It is utterly unrealistic to pretend otherwise. So, we need to scale up a massive global carbon dioxide disposal industry.” Allen adds, however, that discussions are needed about how CCS is funded. “It doesn’t make sense for private companies to make massive profits selling fossil fuels while taxpayers pay to clean up the mess.”

Out of options

Globally there are around 45 commercial facilities that capture about 50 million tonnes of carbon annually, roughly 0.14% of global emissions. According to the IEA, up to 435 million tonnes of carbon could be captured every year by 2030, depending on the progress of more than 700 announced CCS projects.

One key part of the UK government’s plans is to use CCS to produce so-called “blue” hydrogen. Most hydrogen is currently made by heating methane from natural gas with a catalyst, producing carbon monoxide and carbon dioxide as by-products. Blue hydrogen involves capturing and storing those by-products, thereby cutting carbon emissions.

But critics warn that blue hydrogen continues our reliance on fossil fuels and risks leaks along the natural gas supply chain. There are also concerns about its commercial feasibility. The Norwegian energy firm Equinor, which is set to build several UK-based hydrogen plants, has recently abandoned plans to pipe blue hydrogen to Germany, citing cost and lack of demand.

“The hydrogen pipeline hasn’t proved to be viable,” Equinor spokesperson Magnus Frantzen Eidsvold told Reuters, adding that its plans to produce hydrogen had been “put aside”. Shell has also scrapped plans for a blue hydrogen plant in Norway, saying that the market for the fuel had failed to materialise.

To meet our climate targets, we do face difficult choices. There is no easy way to get there

Jessica Jewell

According to the Institute for Energy Economics and Financial Analysis (IEEFA), CCS “is costly, complex and risky with a history of underperformance and delays”. It believes that money earmarked for CCS would be better spent on proven decarbonisation technologies such as buildings insulation, renewable power, heat pumps and electric vehicles. It says the UK’s plans will make it “more reliant on fossil gas imports” and send “the wrong signal internationally about the need to stop expanding fossil fuel infrastructure”.

After delays to several CCS projects in the EU, there are also questions around progress on its target to store 50 million tonnes of carbon by 2030. Press reports, have recently revealed, for example, that a pipeline connecting Germany’s Rhine-Ruhr industrial heartland to a Dutch undersea carbon storage project will not come online until at least 2032.

Jessica Jewell, an energy expert at Chalmers University in Sweden, and colleagues have also found that CCS plants have a failure rate of about 90% largely because of poor investment prospects (Nature Climate Change 14 1047). “If we want CCS to expand and be taken more seriously, we have to make projects more profitable and make the financial picture work for investors,” Jewell told Physics World.

Subsidies like the UK plan could do so, she says, pointing out that wind power, for example, initially benefited from government support to bring costs down. Jewell’s research suggests that by cutting failure rates and enabling CCS to grow at the pace wind power did in the 2000s, it could capture a “not insignificant” 600 gigatonnes of carbon dioxide by 2100, which could help decarbonise heavy industry.

That view is echoed by Marcelle McManus, director of the Centre for Sustainable Energy Systems at the University of Bath, who says that decarbonising major industries such as cement, steel and chemicals is challenging and will benefit from CCS. “We are in a crisis and need all of the options available,” she says. “We don’t currently have enough renewable electricity to meet our needs, and some industrial processes are very hard to electrify.”

Although McManus admits we need “some storage of carbon”, she says it is vital to “create the pathways and technologies for a defossilised future”. CCS alone is not the answer and that, says Jewell, means rapidly expanding low carbon technologies like wind, solar and electric vehicles. “To meet our climate targets, we do face difficult choices. There is no easy way to get there.”

From melanoma to malaria: photoacoustic device detects disease without taking a single drop of blood

Malaria remains a serious health concern, with annual deaths increasing yearly since 2019 and almost half of the world’s population at risk of infection. Existing diagnostic tests are less than optimal and all rely on obtaining an invasive blood sample. Now, a research collaboration from USA and Cameroon has demonstrated a device that can non-invasively detect this potentially deadly infection without requiring a single drop of blood.

Currently, malaria is diagnosed using optical microscopy or antigen-based rapid diagnostic tests, but both methods have low sensitivity. Polymerase chain reaction (PCR) tests are more sensitive, but still require blood sampling. The new platform – Cytophone – uses photoacoustic flow cytometry (PAFC) to rapidly identify malaria-infected red blood cells via a small probe placed on the back of the hand.

PAFC works by delivering low-energy laser pulses through the skin into a blood vessel and recording the thermoacoustic signals generated by absorbers in circulating blood. Cytophone, invented by Vladimir Zharov from the University of Arkansas for Medical Science, was originally developed as a universal diagnostic platform and first tested clinically for detection of cancerous melanoma cells.

“We selected melanoma because of the possibility of performing label-free detection of circulating cells using melanin as an endogenous biomarker,” explains Zharov. “This avoids the need for in vivo labelling by injecting contrast agents into blood.” For malaria diagnosis, Cytophone detects haemozoin, an iron crystal that accumulates in red blood cells infected with malaria parasites. These haemozoin biocrystals have unique magnetic and optical properties, making them a potential diagnostic target.

Photoacoustic detection
Photoacoustic detection Schematic of the focused ultrasound transducer array assessing a blood network. (Courtesy: Nat. Commun. 10.1038/s41467-024-53243-z)

“The similarity between melanin and haemozoin biomarkers, especially the high photoacoustic contrast above the blood background, motivated us to bring a label-free malaria test with no blood drawing to malaria-endemic areas,” Zharov tells Physics World. “To build a clinical prototype for the Cameroon study we used a similar platform and just selected a smaller laser to make the device more portable.”

The Cytophone prototype uses a 1064 nm laser with a linear beam shape and a high pulse rate to interrogate fast moving blood cells within blood vessels. Haemozoin nanocrystals in infected red blood cells absorb this light (more strongly than haemoglobin in normal red blood cells), heat up and expand, generating acoustic waves. These signals are detected by an array of 16 tiny ultrasound transducers in acoustic contact with the skin. The transducers have focal volumes oriented in a line across the vessel, which increases sensitivity and resolution, and simplifies probe navigation.

In vivo testing

Zharov and collaborators – also from Yale School of Public Health and the University of Yaoundé I – tested the Cytophone in 30 Cameroonian adults diagnosed with uncomplicated malaria. They used data from 10 patients to optimize device performance and assess safety. They then performed a longitudinal study in the other 20 patients, who attended four or five times at up to 37 days following antimalarial therapy, contributing 94 visits in total.

Photoacoustic waveforms and traces from infected blood cells have a particular shape and duration, and a different time delay to that of background skin signals. The team used these features to optimize signal processing algorithms with appropriate averaging, filtration and gating to identify true signals arising from infected red blood cells. As the study subjects all had dark skin with high melanin content, this time-resolved detection also helped to avoid interference from skin melanin.

On visit 1 (the day of diagnosis), 19/20 patients had detectable photoacoustic signals. Following treatment, these signals consistently decreased with each visit. Cytophone-positive samples exhibited median photoacoustic peak rates of 1.73, 1.63, 1.18 and 0.74 peaks/min on visits 1–4, respectively. One participant had a positive signal on visit 5 (day 30). The results confirm that Cytophone is sensitive enough to detect low levels of parasites in infected blood.

The researchers note that Cytophone detected the most common and deadliest species of malaria parasite, as well as one infection by a less common species and two mixed infections. “That was a really exciting proof-of-concept with the first generation of this platform,” says co-lead author Sunil Parikh in a press statement. “I think one key part of the next phase is going to involve demonstrating whether or not the device can detect and distinguish between species.”

The research team
Team work The researchers from the USA and Cameroon are using photoacoustic flow cytometry to rapidly detect malaria infection. (Courtesy: Sunil Parikh)

Performance comparison

Compared with invasive microscopy-based detection, Cytophone demonstrated 95% sensitivity at the first visit and 90% sensitivity during the follow-up period, with 69% specificity and an area under the ROC curve of 0.84, suggesting excellent diagnostic performance. Cytophone also approached the diagnostic performance of standard PCR tests, with scope for further improvement.

Staff required just 4–6 h of training to operate Cytophone, plus a few days experience to achieve optimal probe placement. And with minimal consumables required and the increasing affordability of lasers, the researchers estimate that the cost per malaria diagnosis will be low. The study also confirmed that the safety of the Cytophone device. “Cytophone has the potential to be a breakthrough device allowing for non-invasive, rapid, label-free and safe in vivo diagnosis of malaria,” they conclude.

The researchers are now performing further malaria-related clinical studies focusing on asymptomatic individuals and children (for whom the needle-free aspect is particularly important). Simultaneously, they are continuing melanoma trials to detect early-stage disease and investigating the use of Cytophone to detect circulating blood clots in stroke patients.

“We are integrating multiple innovations to further enhance Cytophone’s sensitivity and specificity,” says Zharov. “We are also developing a cost-effective wearable Cytophone for continuous monitoring of disease progression and early warning of the risk of deadly disease.”

The study is described in Nature Communications.

Copyright © 2026 by IOP Publishing Ltd and individual contributors